Medincell Sa Stock Return On Equity
MDCLF Stock | USD 6.98 0.00 0.00% |
MedinCell SA fundamentals help investors to digest information that contributes to MedinCell's financial success or failures. It also enables traders to predict the movement of MedinCell Pink Sheet. The fundamental analysis module provides a way to measure MedinCell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MedinCell pink sheet.
MedinCell |
MedinCell SA Company Return On Equity Analysis
MedinCell's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition |
Based on the latest financial disclosure, MedinCell SA has a Return On Equity of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 100.0% lower than that of the firm.
MedinCell Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MedinCell's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of MedinCell could also be used in its relative valuation, which is a method of valuing MedinCell by comparing valuation metrics of similar companies.MedinCell is currently under evaluation in return on equity category among its peers.
MedinCell Fundamentals
Return On Asset | -0.4 | |||
Operating Margin | (3.25) % | |||
Current Valuation | 190.33 M | |||
Shares Outstanding | 25.22 M | |||
Shares Owned By Insiders | 47.61 % | |||
Shares Owned By Institutions | 19.00 % | |||
Price To Book | 34.52 X | |||
Price To Sales | 31.58 X | |||
Revenue | 4.09 M | |||
Gross Profit | 4.09 M | |||
EBITDA | (21.45 M) | |||
Net Income | (24.81 M) | |||
Cash And Equivalents | 34.39 M | |||
Cash Per Share | 1.38 X | |||
Total Debt | 16.25 M | |||
Debt To Equity | 4.86 % | |||
Current Ratio | 2.84 X | |||
Book Value Per Share | (1.04) X | |||
Cash Flow From Operations | (21.36 M) | |||
Earnings Per Share | (0.88) X | |||
Number Of Employees | 151 | |||
Beta | 1.02 | |||
Market Capitalization | 244.65 M | |||
Total Asset | 44.3 M | |||
Z Score | 9.0 | |||
Net Asset | 44.3 M |
About MedinCell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MedinCell SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedinCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedinCell SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in MedinCell Pink Sheet
MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.